[關(guān)鍵詞]
[摘要]
目的 分析鄂州中心醫(yī)院使用活血化瘀類中藥注射劑治療急性腦梗死的臨床用藥情況,評價其合理性。方法 隨機(jī)抽取2015—2016年急性腦梗死的住院病歷480份,采用藥物利用度、藥品說明書和不良反應(yīng)(ADR)監(jiān)測等評價方法,分析其臨床用藥合理性。結(jié)果 收集到480份病歷,用藥506例/次,涉及12種中藥注射劑;平均用藥頻度(aDDDs)排名前3位的分別為注射用血塞通、疏血通注射液和丹參注射液,藥物利用指數(shù)(DUI)均≤1.0;不合理使用為81例/次,不合理用藥率為16.0%,主要為單次給藥劑量、溶媒種類與說明書推薦不一致、其他藥物混合配伍和同時使用兩種中藥注射劑,西醫(yī)臨床醫(yī)師不合理率顯著大于中醫(yī)執(zhí)業(yè)醫(yī)師(P<0.01);11例發(fā)生ADR,均為皮膚及附件損害。結(jié)論 該院急性腦梗死患者活血化瘀類中藥注射劑使用基本合理,但也存在一些不合理現(xiàn)象,需進(jìn)一步規(guī)范中藥注射劑的臨床合理用藥。
[Key word]
[Abstract]
Objective To analyze the utilization of traditional Chinese medicine (TCM) injections for invigorating blood circulation and eliminating stasis in patients with acute cerebral infarction in Ezhou Central Hospital, and evaluate the rationality of drug use of this type of drugs.Methods Totally 480 patients with acute cerebral infarction from 2015 to 2016 were randomly stratified extraction, and evaluated by criteria according to drug information, drug utilization research and adverse drug reaction (ADR).Results A total of involving 12 kinds of TCM injections and 506 cases in 480. Drug utilization studies have shown that the top 3 drugs for aDDDs values respectively were Xuesaitong Injection, Shuxuetong Injection and Salvia Injection, and DUI values of all drugs were ≤1.0. Evaluation of rational drug use showed irrational use of 81 cases and irrational rate of 16.0%. Mainly for a single dose or the type of solvent instructions for recommended of drug instructions, mixed other drug compatibility or same use of two kinds of TCM injection, irrational rate of Western medicine practitioners was significantly higher than Chinese medicine practitioners (P<0.01). ADR monitoring showed that ADR occurred in 11 cases, main clinical manifestations were skin and accessories damage.Conclusion The utilization of TCM injections for invigorating blood circulation and eliminating stasis in patients with acute cerebral infarction in our hospital is basically rational yet it far from perfect. The clinical rational use of TCM injection needs to be further regulated.
[中圖分類號]
[基金項目]